In vitro antibacterial activity of a new quinolone, NM394

Ozaki, Masakuni; Matsuda, Masato; Tomii, Yoshifumi; Kimura, Kiyoshi; Kazuno, Kenji; Kitano, Masahiko; Kise, Masahiro; Shibata, Kazuo; Otsuki, Masako; Nishino, Takeshi

doi:10.1128/aac.35.12.2490

Cited by 31 publications

(6 citation statements)

References 11 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro studies have shown that prulifloxacin has a wide spectrum of antibacterial activity against gram-negative and gram-positive strains comparable to or higher than that of other reference drugs [8, 9]. …”

Section: Introductionmentioning

confidence: 99%

Randomized, Double-Blind Study of Prulifloxacin versus Ciprofloxacin in Patients with Acute Exacerbations of Chronic Bronchitis

Grassi

Salvatori²,

Rosignoli³

et al. 2002

Respiration

View full text Add to dashboard Cite

Background: Recently the role of bacteria in acute exacerbations of chronic bronchitis (AECB) as well as antibiotic treatment with selected drugs, especially fluoroquinolones, have been better defined. Objective:To assess the efficacy and safety in patients with AECB of prulifloxacin in comparison with ciprofloxacin. Methods: AECB was defined according to the guidelines for the evaluation of new anti-infective drugs for the treatment of respiratory tract infections (1992). 235 patients took part in the trial; 117 (88 males and 29 females, mean age 64.8 years) received 600 mg prulifloxacin once daily and 118 (91 males and 27 females, mean age 64.5 years) 500 mg ciprofloxacin twice a day, for a duration of 10 days. The study design was randomized, multicenter, double-blind, double-dummy. Efficacy evaluations were performed by comparing pretreatment and posttreatment assessments. The clinical response was determined by 4-point rating scores on cough, dyspnea, and expectoration (volume and appearance). The microbiological response was assessed on sputum specimen. Results: Clinical success was observed in 84.7 and 85% of patients in the prulifloxacin and ciprofloxacin groups, respectively. The 95% confidence interval proved the equivalence of treatments. Both drugs successfully eradicated the most commonly isolated strains, including Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and Pseudomonas aeruginosa. Both treatments were well tolerated. Adverse drug reactions were always of mild or moderate intensity. Conclusion: The study showed that a 10-day course of prulifloxacin is as effective and safe as ciprofloxacin in the treatment of patients with AECB.

show abstract

Section: Introductionmentioning

confidence: 99%

Randomized, Double-Blind Study of Prulifloxacin versus Ciprofloxacin in Patients with Acute Exacerbations of Chronic Bronchitis

Grassi

Salvatori²,

Rosignoli³

et al. 2002

Respiration

View full text Add to dashboard Cite

show abstract

“…Fluoroquinolones have potent antibacterial activity and a broad antibacterial spectrum and are regarded as important chemotherapeutic agents against infections occurring in various sites of the body, such as the urinary tract, respiratory tract, and wounds. Several newer fluoroquinolones, such as sparfloxacin (8), levofloxacin (DR-3355) (2), and NM394 (11), have also been reported.…”

mentioning

confidence: 99%

In vitro activity of T-3761, a new fluoroquinolone

Muratani¹,

Inoue²,

Mitsuhashi³

1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The in vitro activity of T-3761, a new fluoroquinolone antimicrobial agent which has an oxazine ring structure with a cyclopropyl moiety at C-10, was compared with those of other agents against 2,854 clinical isolates. T-3761 had a broad spectrum of activity and had potent activity against gram-positive and -negative bacteria. The MICs of T-3761 against 90% of the methicillin-susceptible Staphylococcus aureus, methicillinsusceptible and -resistant Staphylococcus epidermidis, and Clostridium spp. tested were 0.39 to 6.25 ,g/m!. Its activity was comparable to those of ciprofloxacin and ofloxacin and four-to eightfold greater than those of norfloxacin and fleroxacin, but its activity was two-to eightfold less than that of tosufloxacin. Some isolates of ciprofloxacin-resistant S. aureus (MIC of ciprofloxacin, .3.13 ,ug/ml) were still susceptible to T-3761 (MIC of T-3761, .0.78 ,ug/ml). The MICs of T-3761 against 90%o of the streptococci and enterococci tested were 3.13 to 100 ,ug/ml. Its activity was equal to or 2-or 4-fold greater than those of norfloxacin and fleroxacin, equal to or 2-or 4-fold less than those of ofloxacin and ciprofloxacin, and 4-to 16-fold less than that of tosufloxacin. The activity of T-3761 against gram-negative bacteria was usually fourfold greater than those of norfloxacin, ofloxacin, and fleroxacin. Many isolates which were resistant to nonfluoroquinolone agents, such as minocycline-or imipenem-resistant S. aureus, ceftazidime-resistant members of the family Enterobacteriaceae, gentamicin-or imipenem-resistant Pseudomonas aeruginosa, and ampicillin-resistant Haemophilus influenzae and Neisseria gonorrhoeae, were susceptible to T-3761. The MBCs of T-3761 were either equal to or twofold greater than the MICs. The number of viable cells decreased rapidly during incubation with T-3761 at one to four times the MIC. At a concentration of four times the MIC, the frequencies of appearance of spontaneous mutants resistant to T-3761 against S. aureus, Escherichia coli, Serratia marcescens, and P. aeruginosa were 2.2 x 10-8 to <1.2 x 10-9. The 50%o inhibitory concentrations of T-3761 for DNA gyrases isolated from E. coli and P. aeruginosa were 0.88 and 1.9 ,ug/ml, respectively.

show abstract

“…Prulifloxacin (AF3012 or NM441), a new quinolonic antibacterial agent prodrug of AF3013 (or NM394), extensively investigated in Europe and in Japan for the treatment of respiratory and urinary tract infections (11), has a wide spectrum of antibacterial activity against Gram-negative and Gram-positive strains comparable to or higher than that of other reference drugs (12,13,14).…”

Section: Introductionmentioning

confidence: 99%